America Cannot Afford a Setback to Operation Warp Speed Leadership

From 2020-21, Operation Warp Speed served as a crowning achievement of President Trump’s first term. His administration accelerated the development of vaccines to prevent 3 million U.S. deaths – and even more globally – during the Covid-19 pandemic.

The vaccines avoided nearly 20 million hospitalizations and $1.15 trillion in health costs. A University of Chicago study recently determined at least 699,110 life years in the U.S. were saved, producing a direct economic benefit of around $371.6 billion and another $933.1 billion in increased economic activity. Therapeutics not only helped President Trump recover from Covid in 2020, but they also reduced the burden of illness for millions of others across the U.S.

But those victories are not self-sustaining. Leaders in the current Trump administration should not walk back the President’s success.

Last month, HHS canceled government funding for mRNA technology and vaccine research, shelving promising developments to protect Americans from bird flu and other threats. In addition, leadership churn at key health agencies has eroded the institutional expertise that enabled Operation Warp Speed and helped America rebound much more quickly than the rest of the world.

Trump’s support of science-backed American ingenuity shows what is possible when the government reduces red tape, provides direct support, and aligns with private industry behind a common mission. Through Operation Warp Speed, vaccine candidates were funded in parallel, reducing delays between research phases and investments. Vaccine development and building manufacturing capacity happened simultaneously instead of sequentially, and government contracts guaranteed purchases that reduced financial risks of making such huge investments.

The focused development and aggressive distribution built a model of how to accelerate life sciences research while still protecting safety and accountability.

From lab theory to life-saving practice, deploying mRNA as a vehicle for the vaccines was a great breakthrough of the pandemic. The potential outcomes from mRNA platforms extend far beyond Covid with the capacity to develop cancer vaccines, rare-disease therapies, and universal flu shots – among other life-saving applications.

The next great victory is under direct threat now.

In March, reports confirmed China approved its first domestically developed mRNA vaccine, signaling that American leadership is in jeopardy. While the U.S. is pulling back, the European Union has invested over a billion euro into mRNA platforms, positioning itself to lead in cancer immunotherapy and pandemic preparedness. Conversely, U.S. biotech firms are laying off researchers and closing labs because federal support is drying up.

A promising technology and U.S. pipeline that could transform medicine are stalling.

During the pandemic, America showed the world the power of being an innovative nation. Doing so requires defending the gains, protecting the science, and building on one of the greatest public health achievements in history.